Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of “Buy” from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have earned an average recommendation of “Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is $61.40.

HROW has been the subject of several research reports. BTIG Research began coverage on shares of Harrow in a research report on Thursday, June 12th. They issued a “buy” rating and a $62.00 price target for the company. HC Wainwright lifted their price objective on shares of Harrow from $57.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, May 12th. B. Riley cut their price objective on shares of Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Finally, William Blair began coverage on shares of Harrow in a report on Tuesday, June 10th. They set an “outperform” rating on the stock.

Hedge Funds Weigh In On Harrow

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in shares of Harrow by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 1,872,100 shares of the company’s stock worth $62,809,000 after buying an additional 5,225 shares during the last quarter. Braidwell LP raised its stake in Harrow by 5.5% in the 1st quarter. Braidwell LP now owns 956,839 shares of the company’s stock valued at $25,452,000 after acquiring an additional 49,800 shares during the period. D. E. Shaw & Co. Inc. raised its stake in Harrow by 6.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company’s stock valued at $22,301,000 after acquiring an additional 41,896 shares during the period. Royce & Associates LP raised its stake in Harrow by 12.0% in the 1st quarter. Royce & Associates LP now owns 327,096 shares of the company’s stock valued at $8,701,000 after acquiring an additional 35,006 shares during the period. Finally, Northern Trust Corp raised its stake in Harrow by 7.5% in the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company’s stock valued at $10,705,000 after acquiring an additional 22,266 shares during the period. 72.76% of the stock is owned by hedge funds and other institutional investors.

Harrow Stock Performance

NASDAQ:HROW opened at $31.54 on Thursday. The company has a fifty day moving average of $26.35 and a 200-day moving average of $29.44. The firm has a market capitalization of $1.16 billion, a P/E ratio of -33.55 and a beta of 0.40. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow has a twelve month low of $16.87 and a twelve month high of $59.23.

Harrow (NASDAQ:HROW) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The business had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. As a group, sell-side analysts anticipate that Harrow will post -0.53 EPS for the current year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.